Payment overview · 2025
General Payments
$16.57
1 reported records · 1 companies
Healthcare provider profile · identity verified
Katie E Thompson, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PLYMOUTH, WI · NPI 1760911721
Verified facts
What the public records show
CMS Open Payments records show Katie E Thompson, DO received $16.57 in general payments during 2025 across 1 reported records.
Astellas Pharma US Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.57 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $16.57 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 859 | 229 |
| Losartan Potassium | Losartan Potassium | 675 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 618 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 558 | 153 |
| Omeprazole | Omeprazole | 512 | 136 |
| Metoprolol Succinate | Metoprolol Succinate | 413 | 113 |
| Warfarin Sodium | Warfarin Sodium | 392 | 150 |
| Lisinopril | Lisinopril | 362 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 358 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 323 | 95 |
| Simvastatin | Simvastatin | 319 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 75 |
| Gabapentin | Gabapentin | 268 | 67 |
| Metformin Hcl Er | Metformin Hcl | 232 | 61 |
| Alendronate Sodium | Alendronate Sodium | 229 | 66 |
| Sertraline Hcl | Sertraline Hcl | 211 | 55 |
| Furosemide | Furosemide | 205 | 66 |
| Metformin Hcl | Metformin Hcl | 197 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 181 | 44 |
| Alprazolam | Alprazolam | 178 | 43 |
| Jardiance | Empagliflozin | 166 | 39 |
| Trazodone Hcl | Trazodone Hcl | 163 | 38 |
| Famotidine | Famotidine | 155 | 41 |
| Spironolactone | Spironolactone | 153 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 51 |
| Allopurinol | Allopurinol | 145 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 45 |
| Potassium Chloride | Potassium Chloride | 137 | 31 |
| Bupropion Xl | Bupropion Hcl | 134 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 35 |
| Ozempic | Semaglutide | 118 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 27 |
| Ezetimibe | Ezetimibe | 112 | 29 |
| Buspirone Hcl | Buspirone Hcl | 111 | 23 |
| Meloxicam | Meloxicam | 107 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 105 | 31 |
| Eliquis | Apixaban | 104 | 25 |
| Glimepiride | Glimepiride | 100 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 18 |
| Montelukast Sodium | Montelukast Sodium | 94 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 19 |
| Tramadol Hcl | Tramadol Hcl | 85 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 18 |
| Lovastatin | Lovastatin | 79 | 19 |
| Carvedilol | Carvedilol | 66 | 16 |
| Glipizide Er | Glipizide | 66 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 51 |
| Pregabalin | Pregabalin | 65 | 13 |
| Finasteride | Finasteride | 64 | 13 |
| Januvia | Sitagliptin Phosphate | 62 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 59 | 14 |
| Atenolol | Atenolol | 57 | 16 |
| Glipizide | Glipizide | 57 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 11 |
| Synthroid | Levothyroxine Sodium | 54 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 19 |
| Nystatin | Nystatin | 53 | 27 |
| Prednisone | Prednisone | 52 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 19 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 14 |
| Lorazepam | Lorazepam | 50 | 21 |
| Sucralfate | Sucralfate | 50 | 14 |
| Estradiol | Estradiol | 45 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 28 |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 27 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Cephalexin | Cephalexin | 31 | 20 |
| Celecoxib | Celecoxib | 30 | 11 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 27 | 16 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 19 |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 13 |
| Naproxen | Naproxen | 19 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16.57 · 1 records | Astellas Pharma US Inc | Xtandi | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error